Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Targeted antibody therapy provides long-lasting relief from neuropathic pain

Pain is a natural protective mechanism that alerts the body to actual or potential injury. But when nerves themselves are damaged, they can generate abnormal pain signals even in the absence of a new injury.

16 Sep 2026

Study confirms continued effectiveness of antibodies and vaccines used to prevent RSV infections

An analysis of more than 60,000 respiratory syncytial virus (RSV) sequences from around the world found that viral variants associated with resistance to current RSV prevention tools remain rare, according to a study published Sept. 16 in Nature.

16 Sep 2026

Harvard scientists design evolutionary traps to stop viral mutations

When a virus mutates, the world usually finds out the hard way. Variants of influenza and SARS‑CoV‑2 can slip past vaccines and antibody drugs before scientists fully understand what has changed.

15 Sep 2026

Natural anti-NMDAR1 antibody may protect the brain following traumatic brain injury

Every year, an estimated 20 million people worldwide sustain a concussion or other traumatic brain injury (TBI), which leads to a two- to four-fold increase in the risk of depression, anxiety and post-traumatic stress disorder (PTSD).

15 Sep 2026

Stage 1 findings support continued pivotal phase evaluation of gotistobart

Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the investigational anti-CTLA-4 antibody gotistobart compared with 10.0 months for patients receiving docetaxel, according to updated findings from Stage 1 of the Phase 3 PRESERVE-003 trial.

15 Sep 2026

Tam-Peli significantly extends survival in relapsed small-cell lung cancer

The phase III TAISHAN-302 trial found that tambotatug pelitecan (Tam-Peli, YL201), a novel anti-B7-H3 antibody-drug conjugate, significantly improved overall survival, progression-free survival and objective response rate compared with topotecan in patients with relapsed small-cell lung cancer (SCLC).

14 Sep 2026

Ivonescimab shows significant survival benefit for patients with PD-L1-positive NSCLC

Ivonescimab significantly prolonged overall survival compared with pembrolizumab as first-line treatment for patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC), according to a prespecified interim analysis of the phase 3 HARMONi-2 trial presented today at the IASLC 2026 World Conference on Lung Cancer.

14 Sep 2026

Ris-Rez improves survival in patients with relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 trial show that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, significantly improved overall survival compared with topotecan in patients with relapsed small-cell lung cancer (SCLC) whose disease progressed on or after platinum-based chemotherapy.

14 Sep 2026

Low discontinuation rates confirm manageable safety of iza-bren

An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase 3 IZABRIGHT-Lung01 registrational study.

12 Sep 2026

Tumor DNA clearance reaches 39% in novel immunomodulator and ADC combination

The investigational combination of pumitamig and elfetabart drozuntecan (elfe-D) demonstrated a manageable safety profile and encouraging early antitumor activity in patients with small cell lung cancer (SCLC), according to first clinical data from the ongoing Phase 1b/2 BNT324-01 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

12 Sep 2026

Targeted nanoparticles strengthen anti-cancer immune responses in tumors

Adelaide University researchers have developed a new way of using mRNA technology to reprogram tumor-supporting immune cells and strengthen the body's anti-cancer immune response.

11 Sep 2026

Study shows mRNA vaccines trigger more diverse flu antibody responses

Influenza remains a major global health challenge as continual antigenic drift can limit the breadth and durability of vaccine-induced antibody responses, requiring frequent vaccine updates.

11 Sep 2026

Avoiding antibody-dependent enhancement enables dengue prevention and treatment

Dengue virus is one of the most widespread vector-borne viral pathogens in the world. Nearly 400 million dengue virus infections occur each year, resulting in approximately 20,000 deaths.

10 Sep 2026

New nanobody antivenom offers broad protection against Indian cobras

Snakebite is a neglected tropical disease, causing hundreds of thousands of deaths and disabilities each year. India alone reports nearly 50,000 deaths every year, the most by snakebite in the world.

9 Sep 2026

Gut infection leaves long-lasting immune ‘memories’ at the brain’s borders in mice

In mice, intestinal infections reshaped dural CD4+ T-cell populations and seeded the brain’s outer meningeal border with antigen-specific memory cells that persisted for months and mounted rapid recall responses to bloodborne antigens. Oral priming was associated with reduced Salmonella spread to the brain and modest cross-protection in an engineered shared-antigen Candida model, although the researchers could not definitively prove that dural CD4+ T cells alone caused the protection.

9 Sep 2026

New AI method tracks immune responses without known antibody databases

A research team comprising Associate Professor FUNAKOSHI Yohei, Associate Professor YAKUSHIJIN Kimikazu, Professor MINAMI Hironobu, and Associate Professor OHJI Goh of Kobe University, together with graduate student MASUDA Genki, then-graduate student IIZUMI Shunsuke, Associate Professor OHUE Masahito, and colleagues at the Institute of Science Tokyo, has developed a new analysis method, LM-QASAS.

9 Sep 2026

Johns Hopkins researchers identify human resistin as a key driver of inflammation

Researchers at Johns Hopkins Medicine have uncovered a critical biological mechanism that helps explain how inflammation is triggered and sustained in a wide range of diseases-highlighting a promising avenue for future therapeutic development.

9 Sep 2026

Study uncovers cellular mechanisms behind long-lasting antibody responses

A team led by investigators from the University of Osaka uncovers cellular mechanisms that favor long-lived antibody responses, providing insights that may help researchers design vaccines that provide longer-lasting protection against infection.

9 Sep 2026

Retinal immune cell gateway may unlock targeted uveitis treatments

As part of an effort to understand the molecules and mechanisms that regulate transendothelial migration in different vascular beds of the body, researchers focused on the blood vessels of the retina, part of the blood-brain barrier.

8 Sep 2026

New biologic therapy significantly reduces COPD flare-ups in trials

Two international clinical trials led in part by researchers at the University of Pittsburgh School of Medicine found that the investigational biologic therapy tozorakimab significantly reduced chronic obstructive pulmonary disease (COPD) flare-ups among patients already receiving standard treatment for the disease compared to patients only receiving standard treatment.

8 Sep 2026